Depomed Licenses Acuform® Patents to Janssen Pharmaceuticals, Inc. MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that Janssen Pharmaceuticals, Inc., ...

CAMBRIDGE, Mass. and MENLO PARK, Calif., Jul 27, 2011 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. and Depomed, Inc. today announced that Ironwood has licensed worldwide rights to utilize Depomed ...

BURLINGTON, Mass. and MENLO PARK, Calif., June 20, 2011 (GLOBE NEWSWIRE) -- inVentiv Health, offering best-in-class clinical, consulting and commercial services to the healthcare industry, and Depomed ...

Depomed (DEPO) and Biovail Corp (BVF) announce that the cos have entered into an agreement that provides Biovail with access to DEPO's proprietary AcuForm drug delivery technology for the development ...

MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an ...

MENLO PARK, Calif. Depomed has won summary judgment in a U.S. District Court in a patent infringement case against IVAX, according to published reports. The case involved two patents related to the ...

MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric ...

MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug ...